Xcout IntelNectin Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Nectin Therapeutics among biotechnology companies — ranked by similarity to what Nectin Therapeutics actually does, not by market-cap band.
Subscribe to see Nectin Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Nectin Therapeutics
Nectin Therapeutics is an Israeli biotechnology company developing cancer immunotherapies that target nectin-family proteins, particularly Nectin-4. Its products are intended for oncology patients and healthcare providers treating solid tumors.
Nectin Therapeutics at a glance
Nectin Therapeutics is a biotechnology company headquartered in Israel, founded in 2017. Xcout tracks 10 named people at Nectin Therapeutics, including Yaron Daniely (Chairman and Interim CEO).
Nectin Therapeutics leadership
- Yaron DanielyChairman and Interim CEO
- Eric RowinskyActing Chief Medical Officer
- Keren PazChief Development Officer
- Pini TsukermanChief Scientific Officer
- Guy CinamonVice-President, R&D
- Yaron DanielyChairman and Interim CEO
4 more named people on record for Nectin Therapeutics, with roles, board committees and tenure — see the full roster →
Top 12 Nectin Therapeutics competitors
Ranked by semantic similarity — how close each company is to Nectin Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Affimed Therapeutics is a biotechnology company focused on developing cancer immunotherapies that recruit and activate innate immune cells, particularly natural killer (NK) cells, to attack tumor cells. Its investigational products are intended for oncology patients and are developed for use by cancer-care providers.
Similar biotechnology company
Neotx Holdings Ltd. is a biopharmaceutical company that develops cancer therapeutics and immunotherapies. It conducts clinical trials and researches proprietary technologies aimed at advancing cancer treatment.
Similar biotechnology company
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Biotech
Nektar Therapeutics is a biopharmaceutical firm dedicated to identifying and advancing medical treatments for critical health conditions lacking effective therapies, serving markets across the United States and globally. Its diverse pipeline features several promising candidates: Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinoma of the head and neck, and adjuvant melanoma. This same compound is also being investigated in Phase 2 trials for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer, in Phase 1/2A for squamous cell carcinoma of the head and neck, in Phase 1/2 for various solid tumors, and in Phase 1B for COVID-19. Another asset, NKTR-358, a cytokine Treg stimulant, is progressing through Phase 2 clinical trials for systemic lupus erythematosus and ulcerative colitis, alongside Phase 1B studies for atopic dermatitis and psoriasis. Furthermore, NKTR-255, an IL-15 receptor agonist, is undergoing Phase 1/2 clinical trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. The company's portfolio also includes NKTR-262, a toll-like receptor agonist in Phase 1/2 trials for solid tumors, among other developmental drug candidates. Nektar has established significant collaborative agreements with a wide array of pharmaceutical companies, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Founded in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
Similar biotechnology company
Nexion Therapeutics is a biotechnology company focused on researching and developing innovative therapies designed to improve patient outcomes and enhance quality of life. The company serves the healthcare sector by advancing cutting-edge biotechnological solutions.
Biotech
NextCure, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative immunotherapies. Its core mission is to combat cancer and various other immune-related conditions by reactivating normal immune system function. The company's leading investigational compound, NC318, is currently in Phase II clinical trials, focusing on the treatment of advanced or metastatic solid tumors. Additionally, NextCure is progressing NC410 through Phase I studies; this novel immunomedicine is engineered to counteract immune suppression mediated by Leukocyte-Associated Immunoglobulin-like Receptor 1 (LAIR-1). Another asset, NC762, is an immunotherapeutic designed to target the human B7 homolog 4 protein (B7-H4). Furthermore, NC525, a distinct LAIR-1 antibody, is undergoing preclinical assessment for its potential efficacy against acute myeloid leukemia, specifically targeting blast cells and leukemic stem cells. Beyond these specific pipeline candidates, NextCure's broader research and development efforts encompass the preclinical evaluation of other promising immunomodulatory antibodies and molecules. The company operates under a licensing agreement with Yale University. NextCure, Inc. was established in 2015 and maintains its corporate headquarters in Beltsville, Maryland.
Similar biotechnology company
Galecto Biotech is a biotechnology company developing small-molecule inhibitors targeting galectin proteins and related pathways, with applications in fibrotic diseases and cancer. Its products are intended for patients and healthcare providers, particularly in areas with limited treatment options.
Similar biotechnology company
Pan Cancer T develops pioneering T-cell receptor (TCR-T) cell therapies designed to empower patients' immune systems to target and overcome solid tumors. The company utilizes proprietary gene engineering to enhance T-cell fitness and persistence against unique cancer-specific intracellular targets.
Biotech
KAHR Medical Ltd. is a clinical-stage health technology and biopharmaceutical company developing novel drug pipelines and dual-targeting protein therapeutics for immuno-oncology. The company is headquartered in Israel.
Similar biotechnology company
Notch Therapeutics Inc. is a private biotechnology company founded in 2018 and headquartered in Toronto, Ontario, Canada. The company specializes in the development of engineered T-cell therapies.
Similar biotechnology company
NBE-Therapeutics is a biotechnology company founded in 2012 and headquartered in Basel, Switzerland, focused on developing antibody-drug conjugates for oncology treatments.
Similar biotechnology company
Innovative Cellular Therapeutics is a China-based biotechnology company focused on developing cellular immunotherapies, particularly CAR-T therapies for cancer. It serves patients with hematologic and potentially solid-tumor cancers through clinical development and commercialization of engineered cell therapies.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Nectin Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Nectin Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →